Antihypertensive treatment in people with dementia

Veronika van der Wardt, Pip Logan, Simon Conroy, Rowan Harwood, John Gladman

Abstract

Introduction
The range and magnitude of potential benefits and harms of antihypertensive treatment in people with dementia has not been previously established.

Method
A scoping review to identify potential domains of benefits and harms of antihypertensive therapy in people with dementia was undertaken. Systematic reviews of these domains were undertaken to examine the magnitude of the benefits or harms.

Results
Potential outcome domains identified in the 155 papers in the scoping review were cardio-vascular events, falls, fractures and syncope, depression, orthostatic hypotension, behavioural disturbances, polypharmacy risks, kidney problems, sleep problems, interactions with cholinesterase inhibitors and pain. The systematic reviews across these domains identified relatively few studies done in people with dementia, and no convincing evidence of safety, benefit or harm across any of them.

Discussion
There is no justification for materially different guidance for the treatment of hypertension in people with dementia, but sufficient evidence to warrant particular caution and further research into treatment in this group of patients.

Introduction
The WHO 2012 report “Dementia: a public health priority” estimated that there are 35.6 million people with dementia living at present worldwide. About half of people over 50 years of age have hypertension. While the protective effects of antihypertensive treatment against cardiovascular events have been established in numerous clinical trials for different age groups, including the very old, people with dementia have been consistently excluded from these studies. The favourable benefit to risk ratio seen in studies of hypertension treatment in fit older people might not apply if
people with dementia are at a higher risk from the side effects of anti-hypertensive treatment than people with normal cognition (for example through falls or other adverse drug effects), and if they are less likely to be recognised or reported than in those with normal cognition. Therefore management of hypertension in people with dementia may need to be different from in those with normal cognition\textsuperscript{6}. However, current guidelines for the treatment of hypertension do not provide specific advice for people with dementia.

There have been no reviews to comprehensively examine studies investigating the range of outcomes (including harmful effects) of antihypertensive treatment in people with dementia. Such work is important to clarify whether there is a case for altered guidance for the management of hypertension in people with dementia.

**Methods**

A two stage process was undertaken. In the first stage, a scoping review\textsuperscript{7} was undertaken to identify the range of outcomes of antihypertensive treatment in people with dementia. In the second stage, systematic reviews were undertaken for each of the main areas of harmful or adverse outcomes identified in the first stage.

**Stage 1: scoping review**

**Protocol**

The scoping review was based on a pre-defined protocol to search and identify relevant research articles.

**Eligibility**

Inclusion: All articles reporting original research regarding the treatment of hypertension in people with dementia were included. No publication date limit was applied

Exclusion: All studies investigating hypertension as a risk factor for dementia; effects on carers; specific non-dementia diseases (e.g. cancer) and rarer forms of dementia (Korsakoff’s syndrome, dementia due to HIV, normal pressure hydrocephalus, CADASIL); animal studies and non-English
language articles. As effects of antihypertensive drugs on the progression of dementia have been reviewed elsewhere\(^8\text{-}^9\), they were excluded from the literature analysis.

*Information sources*

Pubmed, Embase, Web of Science and the Cochrane library databases were searched.

*Search*

The search for articles took place from July 2012 and was updated in February 2013. Searches were limited to English language human research articles. Search terms included combinations of ‘hypertension’, ‘antihypertensive drug’, ‘antihypertensive treatment’ or ‘blood pressure’ in combination with ‘dementia’ or ‘Alzheimer’s disease’

*Selection*

Duplicates were removed, titles and abstracts were examined by one person (Vv/dW) and inclusion and exclusion criteria applied. Full text versions of the remaining papers were obtained and assessed again based on inclusion and exclusion criteria. The remaining relevant articles were used to identify the range of outcomes examined in scientific articles.

*Data collection*

Main outcome variables were recorded and categorized into topics.

*Analysis*

The number of papers examining each outcome was tabulated.

*Stage 2 systematic reviews*

*Protocol*

The systematic reviews were based on a pre-defined protocol to search and identify relevant research papers.
Eligibility

Inclusion: All articles reporting original research regarding antihypertensive treatment in people with dementia and the topic identified in stage 1 were included. No publication date limit was applied.

Exclusion: As in stage 1. Studies which did not include antihypertensive treatment in any form in the analysis (as composite variable or individual medication classes) were also excluded.

Information sources

Pubmed, Embase, Web of Science and the Cochrane library databases were searched.

Search

Articles were searched until June 2013 publication dates. Searches were limited to English language and, where possible, human research articles. Search terms for stage 2 included ‘antihypertensive’ or antihypertensive drug classes (‘diuretics’, ‘beta blockers’, ‘calcium channel blockers’, ‘angiotensin receptor blockers’ and ‘ACE inhibitors’) in combination with ‘dementia’ or ‘Alzheimer’s disease’ and the topics identified in stage 1 (see flow diagram 1).

Selection

Duplicates were removed, titles and abstracts were examined by one person (VvdW) and inclusion and exclusion criteria applied. Full text versions of the remaining papers were obtained and assessed based on inclusion and exclusion criteria. The remaining relevant articles were included and the number of papers examining each topic was recorded.

Data collection

Methods and results were extracted to record purpose of the study, design, sample size, main measurements and results of each study.

Analysis

Method sections of papers were examined to determine level of evidence. Results were compared and analysed regarding the effect of antihypertensive treatment on the topic in question.
Results

Stage 1 - Scoping review

Figure 1 shows that 155 papers entered this review.

Figure 1 Scoping review

7715 articles identified through Pubmed, Embase, Web of Science and the Cochrane library

5382 articles eliminated based on exclusion criteria applied to titles

2333 articles after exclusion criteria were applied to title

1892 articles eliminated based on exclusion criteria applied to abstract

441 articles after exclusion criteria were applied to abstracts; full text versions were examined

286 articles eliminated based on exclusion criteria

155 articles remained in the scoping review:

- Cardio-vascular events (30)
- Falls, fractures, syncope (26)
- Depression (20)
- Hypotension (20)
- Behavioural disturbances (15)
- Polypharmacy (12)
- Kidneys (15)
- Sleep (8)
- Cholinesterase Inhibitors (5)
- Pain (4)

Ten main outcome themes of effects of antihypertensive treatment in people with dementia emerged from the 155 papers in the scoping review (flow diagram 1); cardio-vascular events, falls, fractures and syncope, depression, hypotension, behavioural disturbances, polypharmacy, kidney problems, sleep problems, cholinesterase inhibitors and pain. The articles identified in the last stage of the scoping review were also included into the stage 2 analysis.

Stage 2 – Systematic reviews
Table 1 shows a summary of the findings of the searches undertaken in the systematic reviews of the topics identified in the scoping review.

Table 1 Search terms ‘dementia’ or ‘Alzheimer’s’ in combination with antihypertensive, diuretics, beta blockers, calcium channel blockers, angiotensin receptor blockers or ACE inhibitors

<table>
<thead>
<tr>
<th>Search terms</th>
<th>No. of articles for which full texts were obtained</th>
<th>No. of articles investigating effects of antihypertensive treatment in people with dementia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stroke, cardiovascular</td>
<td>107</td>
<td>5</td>
</tr>
<tr>
<td>Falls, fractures, syncope</td>
<td>58</td>
<td>4</td>
</tr>
<tr>
<td>Behavioural problems, aggression, agitation, apathy</td>
<td>13</td>
<td>5</td>
</tr>
<tr>
<td>Depression</td>
<td>18</td>
<td>2</td>
</tr>
<tr>
<td>Sleep, insomnia, pain, kidney, renal problems, incontinence</td>
<td>39</td>
<td>2</td>
</tr>
<tr>
<td>Eyes, retinal, glaucoma</td>
<td>15</td>
<td>0</td>
</tr>
<tr>
<td>Cholinesterase inhibitors</td>
<td>15</td>
<td>4</td>
</tr>
<tr>
<td>Polypharmacy</td>
<td>23</td>
<td>2</td>
</tr>
<tr>
<td>Hypotension</td>
<td>20</td>
<td>2</td>
</tr>
</tbody>
</table>

1 **Cardio- and cerebrovascular events**

In total, four studies examined the effects of antihypertensive medication on cardio- and cerebrovascular events in people with dementia (see table 2), with antihypertensives either as main independent variable (three studies) or as control variable (one study).

No randomized controlled placebo trials have been conducted in this area. In people with dementia, two randomized controlled trials investigated the effects of calcium channel blockers (CCBs) in an intention-to-treat, a efficacy and a safety analysis\(^{10-12}\). For both trials, main outcome was cognition but
the safety analysis included cardio- and cerebrovascular events, which were reported as adverse events. The studies compared a control group against a treatment group using CCBs. Both groups were allowed to continue with unspecified antihypertensive treatment as prescribed before the beginning of the study except alpha methylldopa. The results showed that the control group had significantly more adverse (cerebrovascular) events than the treatment group\textsuperscript{11-12}. For cardiovascular events the trend was similar but reached significance in only one of the studies\textsuperscript{12}. In a subgroup analysis of participants with sub-cortical vascular dementia\textsuperscript{13}, no significant differences in these adverse events were found, although again the same trend was observed (fewer events in the treatment group). One study was a non-randomized six weeks open label trial including people with dementia into the safety of Nivladipine (CCB)\textsuperscript{14}. There was no significant difference in adverse events, but this was a very short period of follow up.

In addition, a prognostic cohort study including a large group of people diagnosed with dementia investigated the effects of angiotensin receptor blockers and ACE inhibitors on the risk of hospitalization and mortality while controlling for cerebro-and cardiovascular events\textsuperscript{10}. The results showed that while there was no significant association between angiotensin receptor blockers and risk for hospitalisation or mortality, ACE inhibitors significantly increased the risk for mortality but not for hospitalisation. This association remained significant after controlling for coronary heart disease, stroke and congestive heart failure.

Falls, fractures and syncope
The risk of falls and fractures is higher in people with dementia compared to those without\textsuperscript{15-17}. In addition, some antihypertensive treatments have been shown to increase the risk for falls and fractures in older people\textsuperscript{18-19}. However, this review found no evidence from randomized controlled trials for the risk of falls due to antihypertensive medication in people with dementia. This review identified four prospective cohort studies, two of those investigating the association between falls risk and antihypertensive medication in people with dementia\textsuperscript{20-22}, and a further two examining the association of falls risk with cardiovascular medication\textsuperscript{23-24} (Table 2). Cardiovascular medication included antihypertensive drugs as well as anticoagulants and antiplatelet agents.
The findings showed conflicting results in people with dementia. Examining risk factors for falls in people with and without dementia, Eriksson et al.\textsuperscript{20-21} found that taking diuretics was a significant risk factor for falls for people with dementia in a univariate analysis, but this was non-significant when controlled for significant covariates, but taking more than four drugs was a significant risk factor for falling in people with dementia after controlling for significant covariates. Pellfolk et al.\textsuperscript{22} found no significant difference in the use of antihypertensive medication between fallers and non-fallers in people with dementia and therefore did not enter antihypertensive medication in their logistic regression analysis of independent risk factors of falls. However, Allan et al.\textsuperscript{23} reported that cardiovascular medication was a significant predictor of falls in an analysis of all types of dementia combined (Alzheimer’s disease, vascular dementia, dementia with Lewy bodies and Parkinson’s with dementia), as well as when stratified per dementia type. When significant and potentially modifiable predictors were entered into a multivariate analysis, which was stratified by dementia type, cardiovascular medication remained significantly associated with falls. Asada et al.\textsuperscript{24}, on the other hand, found that cardiovascular medication was not a significant contributor to falls-related injuries in people with dementia.

\textit{Behavioural problems}

Only the effects of beta (Propranolol/Pindolol) and alpha blockers (Prazosin) on behavioural symptoms in people with dementia have been investigated in randomised controlled trials (Table 2). All three trials had very small sample sizes (between 6 and 31 participants) but showed a significant beneficial effect of centrally active antihypertensive medication on behavioural problems. Herrmann et al.\textsuperscript{25} showed that verbal aggression was significantly reduced in people using beta-blockers, without a significant change in total aggression. Peskind, Tsuang and Bonner\textsuperscript{26} found no significant association between use of beta blockers and any specific behavioural subscale but a significant effect of beta blocker use on the total behavioural score. A small randomised controlled trial to assess the effect of alpha blockers on behaviour showed that non-significantly greater improvements in the treatment group than in the control group\textsuperscript{27}. A case series study to assess the effect of beta blockers on behaviour in people with dementia\textsuperscript{28} indicated significant improvements for all behavioural measures (except for wandering, which improved on only one scale). Behavioural improvements after using beta blockers were also found in another case study including people with dementia\textsuperscript{29}. Meta-analyses
showed that beta blockers have relatively little effect on cerebro- and cardiovascular events and mortality compared to other antihypertensive drugs\textsuperscript{30-31}, and are more likely to be discontinued\textsuperscript{32}. Other antihypertensive treatments have not been investigated for their effect on behavioural problems.

\textit{Depression}

Antihypertensive treatment, in particular the use of highly lipid-soluble beta blockers, has been associated with depression\textsuperscript{33}. One randomised controlled trial and one cohort study investigated the relationship between antihypertensive treatment and depression in people with dementia. The randomised controlled trial investigated the effect of Nimodipine (CCB) on depression in patients with diagnosed dementia as well as those with mild to moderate cognitive decline on the Global Deterioration scale\textsuperscript{34}. The treatment and control group were allowed to use other medication including antihypertensive treatment. Scores on the Hospital Anxiety and Depression scale improved significantly more in the treatment group than in the control group. In a large cohort study examining the prevalence of depression in people with dementia, Newman\textsuperscript{35} found that beta blocker use was not a significant covariate in the relationship between dementia and diagnosis of major depression. No other antihypertensive drugs were included in the analysis.

\textit{Sleep problems, pain, kidney problems and incontinence}

Although these topics emerged during the first stage of this review, there were only a very few studies investigating the effect of antihypertensive medication in people with dementia (Table 2). Sleep problems are common in people with dementia\textsuperscript{36-37}, and sleep disturbances, in particular obstructive sleep apnoea, have been shown to improve with antihypertensive treatment\textsuperscript{38}. While there are no studies examining the effects of antihypertensive treatment on sleep quality, one prospective cohort study investigated the relationship between sleep disturbances and nocturnal reduction of blood pressure in people with dementia whilst controlling for antihypertensive treatment\textsuperscript{39}. The results showed no significant difference in use of antihypertensive medication between dippers (hypertensive patients who experience a nocturnal reduction in blood pressure) and non-dippers (those who do not). Other sleep disturbances have not been investigated in people with dementia in relation to use of antihypertensive medication.
Some antihypertensive drugs such as beta blockers, angiotensin receptor blockers and ACE inhibitors seem to have beneficial effects on pain in older people without dementia\textsuperscript{40-41}. For people with dementia, however, the association between pain and antihypertensive treatment has not yet been investigated.

The relationship between kidney problems and antihypertensive medication has not been assessed in people with dementia. One cohort study including geriatric emergency patients investigated the association. The results showed that antihypertensive drugs may contribute to an increased risk of a clinically relevant impairment of renal function\textsuperscript{42}. However, although 56\% of the participants were diagnosed with dementia and no separate analysis for this group was conducted.

The effect of antihypertensive drugs on incontinence has been examined by Ruby et al.\textsuperscript{43} in a large cohort study of older people. They reported that use of alpha blockers was significantly associated with urinary incontinence. Ridgeway et al.\textsuperscript{44} investigated the relationship between incontinence and use of antihypertensive medication in a long-term care population with 79\% being diagnosed with dementia. The results indicated that while dementia was significantly associated with urinary and faecal incontinence, antihypertensive medication was not individually related to incontinence. However, a sub-analysis including only people with dementia was not reported.

\textit{Use of Cholinesterase inhibitors}

Cholinesterase inhibitors are commonly used in the mild to moderate stages of Alzheimer’s disease. Several studies investigated the interaction effects between cholinesterase inhibitors and antihypertensive medication (Table 2) although the evidence is limited to cohort studies and population database studies, no randomised controlled trials have been conducted to assess these effects.

The results of a prospective cohort study\textsuperscript{45} showed significant better cognition in those taking antihypertensive drugs compared to those not taking them. Other studies, however, demonstrated that the joint use of antihypertensive medication and cholinesterase inhibitors was associated with a significantly increased risk of serious adverse drug reactions. Grossberg et al.\textsuperscript{46} found no significant interaction between rivastigmine and antihypertensive medication as a group in their cohort study but when analysed separately, the use of diuretics and rivastigmine was related to a significantly higher rate of serious adverse events while centrally acting antihypertensives, ACE inhibitors and calcium
channel blockers were not. Furthermore, the results of two database studies showed that use of antihypertensive treatment was significantly associated with serious adverse drug reactions in patients treated with cholinesterase inhibitors and beta blockers were among the most frequently encountered drugs involved in drug-drug interactions with cholinesterase inhibitors. These studies indicate that the combination of cholinesterase inhibitors and antihypertensive medication might result in benefits (improvement of cognition) as well as harms (serious adverse drug reactions), which might depend on drug class.

**Polypharmacy and inappropriate medications**

All antihypertensive medications contribute to polypharmacy and its harmful effects, but only two cohort studies investigated antihypertensive drug use in the context of polypharmacy in people with dementia (Table 2). A longitudinal cohort study compared drug use between people with and without dementia, showing that people with dementia used significantly more loop diuretics than people without dementia, and significantly less beta blockers and calcium channel blockers. Inappropriate antihypertensive drug use (estimated daily dose in excess of assumed average maintenance dose per day of a drug used for its main indication in an adult) did not differ between people with and without dementia. Montastruc et al. investigated the use of potentially inappropriate medication in people with dementia in a cohort study, showing that 3.1% of people with mild to moderate Alzheimer's disease used inappropriate centrally acting antihypertensive medication and 2.9% used inappropriate short-acting calcium-channel inhibitors.

**Orthostatic hypotension**

Orthostatic hypotension is associated with poorer cognition and occurs significantly more often in people with dementia than without. However, the role of antihypertensive medication in this context is unclear. Again, no randomised controlled trials have been conducted to examine the relationship between antihypertensive treatment and hypotension in people with dementia. The non-randomised open label trial, which looked at safety of Nivladipine for people with dementia, found no significant difference between treatment and control group in the incidence of orthostatic hypotension. In a cross-sectional cohort study, Anderson et al. found that differences in incidence of orthostatic hypotension between people with Alzheimer's disease, Lewy Body dementia and without dementia
were independent of the use of antihypertensive treatment. Mehrabian et al.\textsuperscript{55} confirmed these results in a cohort study including people with memory complaints including dementia when looking at use or no use of antihypertensive treatment (Table 2). While worse cognitive function and number of different antihypertensives were significantly associated with orthostatic hypotension, it was not reported if the number of different antihypertensive drugs was significantly related to orthostatic hypotension for the dementia group separately.
<p>| Area                                | Author &amp; year                  | Research question                                                                 | Design                                                                 | Sample size                                                                                              | Main measurements                                                                                     | Results                                                                                              |
|------------------------------------|-------------------------------|-----------------------------------------------------------------------------------|-------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|
| Cardio- and cerebrovascular events | Kehoe, Davies &amp; Martin (2013) [10] | How do ACE-Is and ARBs affect the risk for hospitalization and mortality in people with dementia? | Prognostic cohort study based on primary care database                   | N=6290 (all with dementia diagnosis and using AHT)                                                      | Health Death Hospitalisation                                                                          | ACE-Is: sig associated with mortality in patients with AD (HR 1.19; CI 1.07-1.33) and combined dementia group (HR 1.20; CI 1.10-1.30) after adjustments but no association with hospitalization; ARBs: no significant associations |
|                                   | Kennelly, &amp; al. (2011) [14]   | Is nivladipine save and tolerable for people with AD?                              | Non-randomized open label trial (6 wks)                                 | Treatment group n=56; control group n=30 all used other AHTs as well                                   | Inappropriate reduction in BP AEs Falls (self report) Orthostatic symptoms                             | No sig. effect on BP after adjustments; no change in OH in either group; no significant difference in reported AEs between groups but more AEs in treatment group 39.0% vs 23.3 in control group. |
|                                   | Pantoni, Bianchi, &amp; al. (2000) [11] | Is nimodipine efficient in improving cognition and slowing deterioration as well as save for people with multi-infarct dementia? | Double blind RCT intention--to-treat (itt), safety and efficacy analyses | Treatment n=128; control n=131; safety analysis n=259; itt n=251, efficacy n=209, all multi-infarct dementia, controls used other AHTs | Functional rating scale ADL Rapid Disability Scale, CDR Clinical Global Impression Cognition AEs and SAEs | AEs and SAEs analysis showed that only cerebro-vascular events were sig. more in placebo group (AE: 6 in treatment vs 17 in placebo group; SAE: 16 in treatment vs 22 in placebo group, Other results concerning cognition or functioning are all non significant. |
|                                   | Pantoni, Rossi &amp; al. (2000) [13] | Is nimodipine efficient in improving cognition and slowing deterioration as well as save for people with subcortical vascular dementia? | Sub analysis of double blind RCT; intention--to-treat (itt), safety and efficacy analyses | Treatment n=45; control n=47; safety analysis n=92; itt n=87, efficacy n=77, all subcortical VaD, controls use other AHTs | Functional rating scale ADL Rapid Disability Scale, CDR Clinical Global Impression cognition AEs and SAEs | Due to low numbers, no statistical significance could be established but more controls than people in treatment group had SAEs and total AEs. More people in treatment group had BP values indicating hypotension |
|                                   | Pantoni, &amp; al. (2005)          | Is nimodipine efficient in                                                        | Double blind RCT intention                                              | Treatment n=124 (baseline)/94 (endpoint); Sandoz Clinical Assessment Geriatric                         | Cognitive decline in some aspects less in treatment group; AEs and                                  |</p>
<table>
<thead>
<tr>
<th>Reference</th>
<th>Dataset</th>
<th>Question</th>
<th>Study Design</th>
<th>Sample Size</th>
<th>Outcome Measures</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>[12]</td>
<td></td>
<td>improving cognition and slowing deterioration as well as save for people with subcortical vascular dementia?</td>
<td>-to-treat (itt), safety and efficacy analyses</td>
<td>control n=118 (baseline)/55 (endpoint); safety analysis n=239; itt n=230, efficacy n=149, all subcortical VaD, controls use other AHTs</td>
<td>Scale Global Deterioration Score, Gait performance test, Nurses Observation Scale, Clinical Global Impression depression</td>
<td>SAE reported sig. more in placebo than treatment group (AE: RR 1.29, CI 1.03-1.61; SAE: RR 1.58, CI 1.03-2.42) in particular cardiovascular and cerebrovascular events – 9 in treatment group vs 28 in placebo group); no sig. effects blood pressure levels.</td>
</tr>
<tr>
<td>Allan &amp; al. (2009) [23]</td>
<td>Falls</td>
<td>What are the modifiable risk factors for falls in people with dementia?</td>
<td>Prospective cohort study (12 mths)</td>
<td>Total n=179, Controls n=39, AD n=38, VD n=32, DLB n=30, PDD n=40</td>
<td>Medical history, CAMCOG, physical activity scale, BMI, mobility, PD rating scale, ADL, depression, behavioural symptoms, autonomic assessment (OH), falls</td>
<td>Cardiovascular medication only: sig. predictor in univariate analysis for all dementia (HR 2.08; CI 1.15-3.75) and when stratified per diagnosis (HR 1.91; CI 1.03-3.54); Trend sig. in multivariate analysis when stratified by diagnosis (HR 1.98; CI 0.994-3.96)</td>
</tr>
<tr>
<td>Asada &amp; al. (1996) [24]</td>
<td>Falls</td>
<td>What are the predictors of fall-related injuries in people with dementia?</td>
<td>Prospective cohort study (12 mths)</td>
<td>Total n = 184 98 controls, 86 people with dementia</td>
<td>Cognition, behavioural problems, ADL, medication, history of falls, visual &amp; hearing acuity, falls</td>
<td>Cardiovascular medication only: non significant contributor to fall-related injuries (OR 0.9; CI 0.6-1.5)</td>
</tr>
<tr>
<td>Eriksson, &amp; al., 2007 [20] (incl. erratum [21])</td>
<td>Falls</td>
<td>What are the risk factors for falls in people with and without dementia?</td>
<td>Prospective cohort study (6 mths)</td>
<td>Total n = 186, 83 without dementia; 103 with dementia</td>
<td>Cognition, vision, hearing, walking ability, ADL, medication, falls</td>
<td>In Erratum: In people with dementia in univariate analysis, taking diuretics was a significant risk factor (IRR 1.86; CI 1.07-3.23). Not significant in multivariate analysis.</td>
</tr>
<tr>
<td>Pellfolk &amp; Gustafsson (2009) [22]</td>
<td>Falls</td>
<td>What are the risk factors for falls in people with dementia?</td>
<td>Prospective study cohort (6 mths)</td>
<td>Total n = 160 people with dementia; of those n= 64 fallers and n= 96 non fallers</td>
<td>Cognition, vision, hearing, ADL, behavioural and psychiatric symptoms, use of medication, falls</td>
<td>No sig. difference in AHT (beta-blockers, CCB, ACE inhibitors, diuretics) between fallers and non-fallers. No effect sizes reported.</td>
</tr>
<tr>
<td><strong>Behavioural problems</strong></td>
<td><strong>Herrmann &amp; al. (2004) [25]</strong></td>
<td><strong>What is the relation between aggression and BB use in AD patients?</strong></td>
<td><strong>RCT (cross-over design); total duration 15 wks</strong></td>
<td><strong>Total n = 11</strong></td>
<td><strong>Aggression (retrospective Overt Aggression Scale), MMSE, Depression, Sig. decrease in verbal aggression in treatment group but not in total aggression score; higher baseline aggression, higher MMSE and lower growth hormone response to clonidine challenge predicted improvement in aggression. No effect size reported.</strong></td>
<td></td>
</tr>
<tr>
<td>-------------------------</td>
<td>--------------------------------</td>
<td>-------------------------------------------------</td>
<td>-------------------------------------------------</td>
<td>-----------------</td>
<td>--------------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td><strong>Peskind, Tsuang &amp; Bonner (2005) [26]</strong></td>
<td><strong>Does propranolol (BB) reduce disruptive behaviour?</strong></td>
<td><strong>RCT (6wks)</strong></td>
<td><strong>Total n = 31 with probable or possible AD; n=17 on BB, n=14 placebo</strong></td>
<td><strong>NPI change, Clinical Global Impression of Change</strong></td>
<td><strong>Overall score of NPI but no individual sub-score sig. improved in treatment group compared to placebo group. However, within treatment group, results showed sig. reductions in agitation/aggression scores and anxiety scores from baseline to follow-up. No effect size reported.</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Shankle, Nielson, &amp; Cotman, (1995) [28]</strong></td>
<td><strong>Does low-dose propranolol (BB) reduce aggression and agitation in people with dementia?</strong></td>
<td><strong>Case series, mean follow-up 6 mths</strong></td>
<td><strong>Total n = 12</strong></td>
<td><strong>Aggression (by proxy; caregiver rating, CMAI, CBQ), propranolol given until aggression stopped</strong></td>
<td><strong>Sig. improvement compared to pre-treatment aggression levels (proxy rating); CMAI showed sig. reduction in physical and verbal aggression and wandering in responders (n =8) only. CBQ showed sig improvements in all subscales for resp. and non-resp. except wandering; lower MMSE correlated with treatment efficacy. No effect size reported.</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Wang &amp; al. (2009) [27]</strong></td>
<td><strong>How effective and tolerable is prazosin (alpha adrenergic blocker) for behavioural symptoms in AD patients?</strong></td>
<td><strong>Double-blind RCT; duration 8 wks</strong></td>
<td><strong>Total n = 24 (n= 11 in treatment group; n=11 in control group at baseline, n=7 in treatment group and n=6 in placebo group at follow up)</strong></td>
<td><strong>Clinical Global Impression of Change and change from baseline in NPI and BPRS; side effects, changes in BP, functional status</strong></td>
<td><strong>Sig. improvement in all behavioural outcome measures in treatment group compared to placebo. Similar side effects, BP levels and functional status. No effect size reported.</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Weiler, Mungas &amp; Bernick</strong></td>
<td><strong>Does propranolol (BB) improve disruptive</strong></td>
<td><strong>6 case studies</strong></td>
<td><strong>N=6 with dementia</strong></td>
<td><strong>By-proxy observations</strong></td>
<td><strong>Improvements in behaviour observed</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(1988) [29]</td>
<td>behaviour?</td>
<td>RCT</td>
<td>N=178 with dementia; n=89 treatment (CCB); n=89 control</td>
<td>depression</td>
<td>Sig. more improvement regarding depression in treatment than placebo group. No effect size reported.</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td><strong>Depression</strong></td>
<td>Ban &amp; al. (1990) [34]</td>
<td>What effects has nimodipine (CCB) in dementia treatment?</td>
<td>Cohort study</td>
<td>n = 2341; n=749 AD; n=208 VaD; n=175 other dementia; of total n = 29 diagnosed with depression</td>
<td>MMSE; cognitive and physical assessments, depression, BB use</td>
<td>BB use was not a sig. covariate in the relationship between dementia and depression (OR not reported)</td>
</tr>
<tr>
<td><strong>Newman (1999) [35]</strong></td>
<td>What is the relationship of AD and VaD to depression?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sleep problems, pain, kidney problems, incontinence</strong></td>
<td>Suzuki, Meguro &amp; Meguro (2011) [39]</td>
<td>Is there an association between sleep disturbance, decreased daily activity and impaired nocturnal reduction in BP in people with dementia?</td>
<td>Prospective cohort study (14 days)</td>
<td>N = 107 with dementia</td>
<td>ADL, ABPM, evaluation of sleep/wake pattern</td>
<td>No sig. differences in use of AHT between dippers and non-dippers or low and high ADL (no effect sizes reported)</td>
</tr>
<tr>
<td><strong>Ridgeway &amp; al. (2008) [44]</strong></td>
<td>Which co-morbidities and medicines are associated with urinary and fecal incontinence in a long-term care population?</td>
<td>Retrospective cohort study</td>
<td>N=67 female residents</td>
<td>Medications, co-morbidities</td>
<td>Dementia was associated with urinary (OR 4.3, CI 1.3-17.4) and fecal (OR 6.8, CI 1.8 – 47.2) incontinence in a multivariate analysis. AHT was not associated with UI or FI (no effect sizes reported).</td>
<td></td>
</tr>
<tr>
<td><strong>Cholinesterase inhibitors</strong></td>
<td>Grossberg &amp; al. (2000) [46]</td>
<td>Are there any adverse pharmacodynamic drug interactions with rivastigmine and other classes of medications?</td>
<td>Prospective cohort study over 6 mnths</td>
<td>N=2459; n=1696 using rivastigmine; n=763 controls</td>
<td>22 types of adverse events</td>
<td>No significant pattern of increase in AEs was found for users of AHT as one group and beta blockers as well as alpha blockers as individual medication types. However, for diuretics, a significant difference was found between people with and without rivastigmine.</td>
</tr>
<tr>
<td>Pariente &amp; al. (2010) [47]</td>
<td>What are factors associated with serious adverse effects?</td>
<td>Population study based on the French 773 reports about cholinesterase inhibitors mentioning a total of</td>
<td>ADRs leading to death, hospitalisation or death, hospitalisation or death, hospitalisation or</td>
<td>Factors associated with serious ADRs were age, use of atypical antipsychotics, use of conventional</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Question</td>
<td>Methodology</td>
<td>Results</td>
<td>Notes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>----------</td>
<td>-------------</td>
<td>---------</td>
<td>-------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rozzini &amp; al. (2005) [45]</td>
<td>What is the relationship between AHT and cholinesterase inhibitors?</td>
<td>Prospective cohort study; 40 wks</td>
<td>N = 416; n=161 AHT users; n = 255 not AHT users</td>
<td>MMSE, ADL, Beta blockers, Calcium channel antagonists</td>
<td>Sig difference between AHT user and non-user in MMSE in favour of users at wk 16 (T2). No sig. difference at T3 (40wks). Sig. higher MMSE for users in those that respond to cholinesterase inhibitors, but not in non-responders. No effect sizes reported.</td>
<td></td>
</tr>
<tr>
<td>Tavassoli &amp; al. (2007) [48]</td>
<td>What are the drug interactions with cholinesterase inhibitors?</td>
<td>Analysis of spontaneous reports regarding cholinesterase inhibitors</td>
<td>N= 1058 spontaneous reports incl. cholinesterase inhibitors</td>
<td>Beta blockers were among the most frequently encountered drugs involved in DDI (83 cases) with cholinesterase inhibitors</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Polypharmacy</td>
<td>Giron &amp; al. (2001) [50]</td>
<td>What is the extent of inappropriate drug use in people with and without dementia?</td>
<td>Prospective cohort study (8-10 yrs)</td>
<td>N=681; n =188 with dementia; n = 493 without dementia</td>
<td>Drug groups; drug duplications</td>
<td>People with dementia were sig. more likely to use high-ceiling diuretics and sig. less likely to use BBs and CCBs than people without dementia; no differences in drug duplication between people with and without dementia (no effect sizes reported).</td>
</tr>
<tr>
<td>Montastruc &amp; al. (2013) [51]</td>
<td>What is the prevalence of potentially inappropriate medication use in people with mild to moderate AD?</td>
<td>Prospective cohort study (4 yrs)</td>
<td>N = 684 with AD</td>
<td>ADL, MMSE, NPI, PIM use</td>
<td>3.1% of sample used inappropriate centrally acting AHT; 2.9% of sample used inappropriate short acting calcium channel inhibitors.</td>
<td></td>
</tr>
<tr>
<td>Orthostatic</td>
<td>Anderson &amp; Is orthostatic</td>
<td>Cross-</td>
<td>AD n = 235;</td>
<td>MMSE, medication, OH occurred sig. more in DLB than</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Hypotension

<table>
<thead>
<tr>
<th>Study</th>
<th>Hypothesis</th>
<th>Study Design</th>
<th>Sample Size</th>
<th>Procedures</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>al. (2008) [54]</td>
<td>Hypotension more common in people with dementia than in those without cognitive impairment?</td>
<td>Sectional cohort study</td>
<td>DLB n = 52; controls n = 62</td>
<td>After resting in supine position: immediately and after 1, 3, 5, 10 mins of standing</td>
<td>in AD, and in AD sig. more than in controls. No sig. difference in AHT between groups. No effect sizes reported.</td>
</tr>
<tr>
<td>Mehrabian &amp; al. (2010) [55]</td>
<td>What is the relationship between orthostatic hypotension (OH) and cognition in people with cognitive impairment?</td>
<td>Cohort study</td>
<td>Total total n = 495 consecutive patients with memory complaints visiting a memory clinic</td>
<td>Sitting and standing (after 1 and 3 min) BP.</td>
<td>Patients with OH used a sig. higher number of AHT than those without OH. OH patients had sig. poorer cognitive function. This was independent of AHT. OH was significantly more often present in VaD, AD, MCI than in cognitively non-impaired individuals in an overall test (no individual differences or effect sizes reported).</td>
</tr>
</tbody>
</table>

* CI refers to a 95% Confidence Interval; ABPM = ambulatory blood pressure monitoring; ACE-I = ACE inhibitor; AD = Alzheimer’s disease; ADL = activities of daily living; ADR = adverse drug reaction; AHT = antihypertensive treatment; ARB = angiotensin receptor blocker; BB = beta blockers; BP = blood pressure; BPRS = Brief Psychiatric Rating Scale; CAMCOG = Cambridge Cognition computerized cognitive test battery; CBQ = California Behavior Questionnaire; CDR = Clinical Dementia Rating; CCB = calcium channel blocker; CMAI = Cohen Mansfield Agitation Inventory; DDI = drug-drug interaction; DLB = dementia with Lewy bodies; FI = fecal incontinence; GFR = glomerular filtration rate; HR = hazard ratio; IRR = incidence rate ratio; MCI = mild cognitive impairment; MMSE = Mini Mental State Examination; mths = months; NPI = Neuropsychiatric Inventory; OH = orthostatic hypotension; OR = odds ratio; PDD = Parkinson’s disease dementia; PIM = potentially inappropriate medication; RCT = randomised controlled trial; SAE = serious adverse event; UI = urinary incontinence; VaD = vascular dementia; wks = weeks
Discussion

The first phase of this review identified several important domains of outcome relevant to the treatment of hypertension in people with dementia – not only cardio-vascular events but also falls, fractures and syncope, depression, orthostatic hypotension, behavioural disturbances, polypharmacy risks, kidney problems, incontinence, sleep problems, interactions with cholinesterase inhibitors and pain could also be affected. The second phase examined each of these areas in turn and concluded that relatively little is known about the effect of antihypertensive therapy upon these outcomes in people with dementia (as opposed to older people in general). From what we found, calcium channel blockers might have a beneficial additional effect upon depression, beta-blockers may reduce behaviour disturbance, ACE inhibitors might increase the risk of mortality, and there was no consistent evidence of any relationship between antihypertensive therapy and falls, orthostatic hypotension or interactions with cholinesterase inhibitors. Overall, relatively few studies of antihypertensive therapy have been undertaken in people with dementia, and there is virtually no information specific to different dementia sub-types.

This review could be subject to a publication bias towards positive outcomes and benefits, and against the reporting of adverse consequences of treatment, which means that the possible benefits the review identified of antihypertensive treatment should be interpreted with caution.

This review adds to the little that is known specifically about the treatment of hypertension in people with dementia. Previous reviews have proposed but not proven that such treatment might delay the onset of dementia\textsuperscript{8,9}. Another review concluded that there is no convincing evidence of the effectiveness of antihypertensive therapy in the reduction of cardiovascular and cerebrovascular events in people with dementia\textsuperscript{56}, which our review has confirmed. This review, however, illustrates the range of potential harms and benefits of antihypertensive therapy in people with dementia beyond those mentioned in most trials of antihypertensive agents – although it found little firm evidence about them.
Given the lack of firm evidence of increased adverse outcomes arising from antihypertensive therapy in people with dementia, there is currently no reason to produce materially different guidelines for the treatment of hypertension in people with dementia, and justifies the current presumption that the favourable evidence drawn from the treatment of non-demented people should be extrapolated to those with dementia. As part of this guidance, the side effects of antihypertensive drugs should be sought on a routine basis: those looking after hypertension in people with dementia may need to gather a collateral history to do so adequately. Our review does not contradict guidance about prescribing in general in frailty states, which would apply to many people in the later stages of dementia: this includes withdrawing preventative medication in those believed to be in their last months of life when the potential benefits diminish in magnitude, and confirming whether the consent to treatment made by patients before the onset of dementia is still valid when they have lost mental capacity. Our review also should not discourage physicians caring for acutely ill people with dementia from withdrawing antihypertensive drugs temporarily while they are cardiovascular instability or are at high risk of problems such as acute kidney injury.

Nevertheless, the lack of evidence of harm or benefit in this group means that there is at least a concern about the safety of antihypertensive treatment and a gap in the evidence base. Given the growing numbers of people with dementia and hence with dementia and hypertension, and growing concerns over both polypharmacy and frailty, we propose that clinicians should audit carefully their treatment of hypertension in this group of patients, trials of safe withdrawal of antihypertensive therapy should be considered for this population (as have been done for the general population) taking the wide range of outcomes identified in this review into account, and more work is required to clarify the factors that should determine when antihypertensive therapy should be withdrawn in the later stages of the dementia process.

References


